Header Logo

Connection

Michael Silverberg to RNA, Viral

This is a "connection" page, showing publications Michael Silverberg has written about RNA, Viral.
Connection Strength

1.049
  1. The Contribution of Socioeconomic Factors to HIV RNA Suppression in Persons With HIV Engaged in Care in the NA-ACCORD. J Acquir Immune Defic Syndr. 2024 Nov 01; 97(3):232-241.
    View in: PubMed
    Score: 0.243
  2. Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data. AIDS Behav. 2020 Jun; 24(6):1784-1792.
    View in: PubMed
    Score: 0.179
  3. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
    View in: PubMed
    Score: 0.147
  4. Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010 Oct 23; 24(16):2469-79.
    View in: PubMed
    Score: 0.092
  5. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007 Sep 12; 21(14):1957-63.
    View in: PubMed
    Score: 0.074
  6. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
    View in: PubMed
    Score: 0.047
  7. Demographic, Insurance, and Health Characteristics of Newly Enrolled HIV-Positive Patients After Implementation of the Affordable Care Act in California. Am J Public Health. 2016 07; 106(7):1211-3.
    View in: PubMed
    Score: 0.034
  8. Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol. 2015 Dec 01; 182(11):952-60.
    View in: PubMed
    Score: 0.033
  9. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013 Oct 15; 208(8):1240-9.
    View in: PubMed
    Score: 0.028
  10. Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
    View in: PubMed
    Score: 0.025
  11. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35.
    View in: PubMed
    Score: 0.024
  12. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26.
    View in: PubMed
    Score: 0.021
  13. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
    View in: PubMed
    Score: 0.020
  14. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
    View in: PubMed
    Score: 0.019
  15. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
    View in: PubMed
    Score: 0.019
  16. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):531-9.
    View in: PubMed
    Score: 0.018
  17. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005 Apr 20; 97(8):577-86.
    View in: PubMed
    Score: 0.016
  18. Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001 Nov 09; 15(16):2101-8.
    View in: PubMed
    Score: 0.012

© 2024 Kaiser Permanente